Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397254 · ClinicalTrials.gov registry record · Phase 4
Two Rizatriptan Prescribing Portions for Treatment of Migraine
A Phase 4 study of Migraine, sponsored by Clinvest.
- Completed
- Registry status
- Phase 4
- Development phase
- 197
- Enrollment target
- 10
- Study locations
NCT00397254 is a Phase 4 study of Migraine that has completed, run by Clinvest. The registered enrollment target is 197 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (45% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00397254, a Phase 4 study of Migraine, has completed, sponsored by Clinvest.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 197 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
Conditions Studied
Interventions
- DRUG rizatriptan
Study Locations (10)
California
- Brian Koffman, MD - Diamond Bar
- San Francisco Clinical Research Center - San Francisco
Missouri
- Clinvest - Springfield
- Mercy Health Research / Ryan Headache Center - St Louis
Florida
- Physician Associates - Oviedo
Georgia
- Dr. B. Abraham, PC - Snellville
Maryland
- Dhiren Shah, MD - Prince Frederick
Michigan
- Westside Family Medical Center - Kalamazoo
North Carolina
- PharmQuest - Greensboro
Pennsylvania
- Thomas Jefferson University Hospital Jefferson Headache Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397254
The ClinicalTrials.gov registry entry for NCT00397254 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (45% lower). The listed sponsor is Clinvest, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which rizatriptan is the first listed.
NCT00397254 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT00397254 about?
NCT00397254 is a clinical study titled "Two Rizatriptan Prescribing Portions for Treatment of Migraine". The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
What is the current status of trial NCT00397254?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 197 participants. The study started on 2006-12. Estimated completion is 2008-01.
What conditions does trial NCT00397254 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT00397254?
The interventions under investigation include: rizatriptan (DRUG).
Who is sponsoring clinical trial NCT00397254?
This trial is sponsored by Clinvest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00397254 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
RECRUITING · Phase 4
-
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
RECRUITING · Phase 4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
RECRUITING · Phase 4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
RECRUITING · Phase 4
-
Nerivio Efficacy Under High-Frequency Use
ACTIVE NOT RECRUITING · Phase 4
-
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.